Loading...
Pharma and Biotech
Helping clients understand disease evolution and stakeholders’ perspectives to stay ahead of competition
What we do
- What is the key population afflicted with the disease?
- How has the disease incidence changed over time?
- What are the key symptoms and implications of the diseases?
- What are the currently available treatments for the disease?
- What is the current disease burden – direct costs, loss of productivity etc.?
- Who are the key players in the treatment ecosystem of the disease?
- How has their share or role evolved over time?
- How is disease incidence, mortality / morbidity, customer LTV, market size and share expected to evolve over time?
- Which population is most affected by the disease?
- How does the disease behavior vary across geographies, age-groups, ethnicity, environment etc.?
- What is the risk of transmission of the disease in healthy population?
- How magnified is the risk of disease infection in exposed population in comparison to unexposed population?
- What is the distribution of the disease in a selected population group?
- Which population is most vulnerable and should mandatorily be screened for the disease?
- Who are the market leaders across different therapeutic areas and geographies?
- Which players have inherent advantages considering recent regulations?
- How does the pipeline of key players look like?
- When is the next patent cliff for generic manufacturers?
- What are the expected strategies (M&A, fundraise, IPO, developed market entry) for key players?
- What is the pace of NDA (New Drug Approval) / ANDA (Abbreviated New Drug Approval) for key players?
- How has the share of key players changed in the last quarter, 6 months, 1 year, 5 years and 10 years?
- What is the severity of the target disease in addressable population?
- What is the rate of discovery and treatment for the disease?
- Which treatments exist for the disease and what is their efficacy?
- What is the degree of patient compliance for the disease treatment?
- Does the treatment efficacy vary with demographics?
- What is the typical patient journey in disease treatment?
- What are the current white gaps in disease treatment?
- Which emerging therapies for the disease appear promising in terms of safety, efficacy, and cost?
- What is the degree of willingness to accept / switch for the emerging therapy?
- What are the proven, typical side effects of the therapy?
- What is the intended plan of scale-up for the therapy?
- What is the expected revenue stream initially and how is it expected to evolve over time?
- What are the challenges associated with the launch and scale-up of emerging therapies?
- What new technologies are being adopted by the industry?
- What are the most recent headwinds / tailwinds in the sector?
- Which are the most profitable therapeutic areas currently?
- What are the challenges currently faced by the pharma players?
- How is digitization helping increase operational efficiencies?
- When is the next patent cliff due?
- What are the newest drugs / biologics approved by US FDA, EU CEP, other regulatory bodies?
- What have been the most promising therapeutic areas in last 5-10 years?
- How much revenues have been recorded by the company / drug in the last financial period?
- How does the unit economics of drug / company look like?
- What is the company’s / drug’s supply chain?
- What has been the historical journey of the company / drug?
- Has the company / drug been involved in any major recalls or audit actions?
- How strong is the company leadership and what is its vision?
- Who are the key competitors in manufacturing of drug / biologic?
- Who is the target audience of the product?
- Is the product substituting any existing product?
- What is the product’s value proposition and differentiation with respect to competitors?
- What is the expected degree of adoption or willingness to switch for the product?
- What is the expected degree of success of the product launch?
- Are there any regulatory clouds surrounding the product?
- What are the key segments using the drug?
- What is the NPS on the drug or therapy type?
- What does the patient like about the drug?
- What is the patient’s degree of choice of the product?
- What doesn’t the patient like about the product – unpalatable dosage form, severe side-effects etc.?
- What is the patient compliance on the drug?
- How does NPS, feedback, KPC and degree of compliance vary across demographics?
- What is the performance of drug since market launch?
- What is the degree of efficacy of the drug?
- How does degree of efficacy vary across demographics, routes of administration, dosage form etc.?
- Has there been any unlabeled harm observed in the patients?
- What is the severity of the harm?
- How does the unlabeled and unidentified harm vary across demographics?
- How was the new issue missed during clinical trials reporting?
- How much revenues have been recorded by the company / drug in the last financial period?
- How does the unit economics of drug / company look like?
- What is the company’s / drug’s supply chain?
- What has been the historical journey of the company / drug?
- Has the company / drug been involved in any major recalls or audit actions?
- How strong is the company leadership and what is its vision?
- Who are the key competitors in manufacturing of drug / biologic?
- What have been the most recent regulations put out by various pharmacopeia?
- What are the implications of most recent regulations on the industry and patients?
- Which parties will be impacted and what is the degree of impact on each of them?
- How is competition responding to the regulations?
- What are the local and international best practices in face of the regulations?
- What is the channel partner’s portfolio with the client?
- What is the partner’s NPS on each portfolio product?
- How does partner’s NPS vary across channel type, margin size, geography and operating model?
- What does the partner like / dislike about the product?
- What are the key improvement areas for the client?
- How does NPS, feedback, KPC and degree of compliance vary across demographics?
- What is the sales force’s effectiveness in terms of standard industry parameters?
- How does client’s sales force effectiveness benchmark with the competition on key parameters?
- How does client’s sales organogram compare with that of the competition?
- What are the local and international best practices to boost effectiveness?
- How has the effectiveness changed over time?
- How does effectiveness vary with product type, channel, geography and incentive schemes?
- How does client’s process cost fare with that of competition?
- What is the structure and breakup of cumulative cost?
- How do individual cost segments compare with competition?
- What are the areas of improvement for the client with respect to competition?
- Does client’s additional cost provide it a differentiation against competition?
- What are the global best practices for cost optimization?
- What are some of the short-term and long-term actions that can help optimise cost?
- What is the potential of select micro-market and what is client’s current share?
- Has how client’s share in micro-market changed over time?
- Is there potential for client’s growth in the select micro-market?
- What would be client’s drivers of growth in the market?
- What are client’s strengths and weaknesses with respect to competition?
- What is the typical investment required to boost share?
- What are some local and global best practices that can help client gain micro-market share?
- What is the degree of brand awareness with respect to competitors?
- What are the key values associated with the brand?
- What are the typical avenues for introducing brand to practitioners and patients?
- What is the effectiveness of various channels for brand introduction?
- How does brand awareness change with demographics and patient ailments?
- How important is brand in the sale process?
- What are some of the best practices to strengthen brand value?
Disease landscaping and forecasting
- What is the key population afflicted with the disease?
- How has the disease incidence changed over time?
- What are the key symptoms and implications of the diseases?
- What are the currently available treatments for the disease?
- What is the current disease burden – direct costs, loss of productivity etc.?
- Who are the key players in the treatment ecosystem of the disease?
- How has their share or role evolved over time?
- How is disease incidence, mortality / morbidity, customer LTV, market size and share expected to evolve over time?
Connect with our experts
Why 1Lattice?
Tech Enabled
Quality of Insights
Reliability of Outcomes
